Page 12 - Dr Reddy’s Laboratories
Company will emerge more stronger and resilient: Dr Reddy's chairman
The company on Tuesday revealed that it was in the process of writing to the USFDA for re-inspection of the three manufacturing sites
 "Company will emerge more stronger and resilient: Dr Reddy's chairman")
Can Dr Reddy's overcome the steep challenges it faces?
Despite assurances, the Indian generics drug major has failed to show any hint of turnaround, however small, from any segment or geography
 "Can Dr Reddy's overcome the steep challenges it faces?")
Dr Reddy's Q1 net down 80% at Rs 126 crore
Pharma major's bottomlines impacted by a decline in volume growth, particularly in the US market and the loss of business in Venezuela
Dr Reddy's Labs Q1 profit slumps 75%
Net profit for the April-June quarter fell to Rs 154 crore from Rs 626 crore the previous year,
 "Dr Reddy's Labs Q1 profit slumps 75%")
Dr Reddy's launches anti-ulcer capsules in US
Drug is generic equivalent of Zegerid capsules, which has a market of $307 million in twelve months to May 2016
 "Dr Reddy's launches anti-ulcer capsules in US")
Dr Reddy's to have stronger quality system by 2016-end: G V Prasad
This follows firm's remediation efforts after USFDA's warning letter over certain compliance issues last year
 "Dr Reddy's to have stronger quality system by 2016-end: G V Prasad")
Dr Reddy's Lab completes share buyback; stock hit seven-month high
The stock outperformed the market by surging 10% as compared to 0.17% rise in Sensex during past eight trading sessions.
 "Dr Reddy's Lab completes share buyback; stock hit seven-month high")
Multiple headwinds for Dr Reddy's in FY17
Price erosion in the US and higher R&D costs are major concerns
 "Multiple headwinds for Dr Reddy's in FY17")
Dr Reddy's recalls 50,000 bottles of Ondansetron tabs in US
USFDA says it's a class II recall, initiated when a drug may cause temporary or reversible adverse health conditions
 "Dr Reddy's recalls 50,000 bottles of Ondansetron tabs in US")
Dr Reddy's profit down 85%
The company saw surge in selling, general and administrative expense surge 7% year-on-year
Dr Reddy's Laboratories announces share buyback offer
The company proposes to spend Rs 1,569.41 crore to buy shares at a maximum price of Rs 3,500 per share
 "Dr Reddy's Laboratories announces share buyback offer")
Dr Reddy's, Japan's Eisai ink licensing pact for anti-cancer agent
Eisai will be responsible for the development and marketing of E7777 in Japan and Asia, while Dr Reddy's holds the option for rights to develop and market the agent in India
Dr Reddy's, TR-Pharm ink pact for biosimilar drugs in Turkey
Biosimilar products will be registered and commercialised by T-Pharm
 "Dr Reddy's, TR-Pharm ink pact for biosimilar drugs in Turkey")
Changes in excise rate rebate claim procedure will impact exporters: Dr Reddy's
Dr Reddy's and other large Indian pharmaceutical companies earn two-thirds of their revenues from exports, said the company's CFO
Dr Reddy's Lab extends rally after board nod for share buyback
The stock rallied 6.5% to Rs 3,154, extending its previous day's 3.6% gain on the National Stock Exchange.
 "Dr Reddy's Lab extends rally after board nod for share buyback")
